Abstr#2111-symptomatic coccidiomycosis more prevalent in pts using steroids with biologics. Nice retrospective study on this unmet need @RheumNow #ACR19

@RheumNow #ACR19 abs2467 multicenter observational study analysis concludes sleep impairment in PsA is mainly mediated by subjective factors like anxiety and pain rather than inflammation https://t.co/q64dhsZILW

Nice study reminding us we need to do a better job of screening for chronic hepatitis B prior ritux (and ALL other forms of immunosuppressive) with HBsAg, HBcAb and HBsAb abstr#2100 @RheumNow #ACR19 @LCalabreseDO https://t.co/s7yogf6qC0

COAST-X: IXE met ASAS 40 and all secondary endpoints in nr-axSpA vs PBO. https://t.co/V0QNfi33eA #ACR19 @RheumNow plenary#2729 #ACRbest https://t.co/VVkEfLpHzs

• Ixekizumab in Non-Radiographic Axial Spondyloarthritis: Primary Results from a …

Is there any data about the safety of 8000u of vitamin A daily? Just asking because I have no idea #ACR19 @RheumNow https://t.co/aLtCOgujdK

• Dr. Rachel Tate on Twitter: "A few of Dr. Sterling West’s pearls for Rheum…

Gout increases risk of fatal & non-fatal CVD events (in pop without previous CVD events) No obvious protection from using Allopurinol Population level study #ACR19 @rheumnow Abst2732 https://t.co/yQu0PjkmIN

Spending and price trending of bDMARDs. https://t.co/gB6xjvialr #ACR19 @RheumNow plenary#2731 https://t.co/YNpwYvTu1y

• Decomposition Analysis of Spending and Price Trends for Biologic Anti-Rheumatic…

Abstr# 2156: Something I had never heard of — Yao Syndrome. This is an adult onset (mean 25.9yo at presentation) autoinflammatory syndrome associated with NOD2 mutations. #ACR19 @RheumNow https://t.co/J71t6uqrSx

"We are all using biosimilars," said Dr. Bykerk, since TNFi approved in the 1990s have faced antigenic drift and changed over the years... #ACR19 @RheumNow

Abstract L06 shows the efficacy of Emapalumab, an IFN-γ mAb, when given to 9 systemic JIA pts who developed macrophage activation syndrome. Highly effective showing ability to lower steroid use #ACR19 #ACRBest https://t.co/OXTwpkyhlq

Yes, you read that right US$5,000,000,000 increase in biological DMARD spending #ACR19 @RheumNow Abs 2731 https://t.co/9Ew5II282Y

#ACR19 Abst#2729 Plenary: Ixekizumab in NR-axSpA Improved ASAS40 at wk16 (32% vs 12% PLBO, NNT~4). Wk52 open label f/u available, but hard to interpret Remember this is a different population (non radiographic) than the upadacitinib trial that was also presented @RheumNow https://t.co/tkYEfiqj7h

Abstr# 2612: Minocycline as an option for refractory calcinosis in scleroderma. 43% of patients reported some improvement. With few options available, this would be something to consider. #ACR19 @rheumnow https://t.co/yXvmUwaxzU

We know ovarian insuff with cyclophosphamide is dose-related, but in SLE data from @EmoryUniversity @emoryhealthcare the absolute numerical diff between success & failure is tighter than I imagined. Other factors at play? Also: time heals some wounds... #ACR19 ABST2293 @RheumNow https://t.co/wI3S4ljjOJ

Dr. Suzanne Li discusses juvenile localized scleroderma disease activity at #ACR19: jLS can cause severe damage. There is no universal activity feature for jLS so need to assess multiple features, such as -Erythema -Violaceous color -Waxy white/yellow #pedsrheum @RheumNow https://t.co/BpszRgHhyr